AXIN1 and neoplasm: A defining strength of AI-HOPE-WNT lies in its ability to dynamically stratify CRC patient cohorts by WNT gene mutation status (e.g., APC, AXIN1/2, RNF43), tumor location, age group, treatment exposure (e.g., FOLFOX), and molecular phenotype (e.g., MSI).